(AOF) – AstraZeneca today announced the successful completion of the acquisition of Icosavax, a US clinical-stage biopharmaceutical company focused on the development of high-potential differentiated vaccines using an innovative virus-like particle (VLP) platform. proteins. The acquisition will leverage AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s late-stage vaccine and immune therapy pipeline with Icosavax’s lead investigational vaccine candidate , IVX-A12.
IVX-A12 is a potentially first-in-class, Phase III-ready combination VLP vaccine that targets both RSV and human metapneumovirus (hMPV), two leading causes of serious respiratory infections and hospitalizations in adults aged 60 and over and those suffering from chronic illnesses such as cardiovascular, renal and respiratory diseases.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
